Efficacy of sodium thiosulfate for the treatment for calciphylaxis

L. Noureddine, M. Landis, N. Patel, Sharon Moe

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background/Aims: Calciphylaxis is a rare condition with dismal prognosis that affects patients with ESRD. Sodium thiosulfate (STS) may play a therapeutic role but its proposed efficacy is based on case reports and thus subject to publication bias. Methods: We identified all patients who received STS for any indication over a 5-year period through pharmacy records of 4 hospitals, retrospectively reviewing medical records for risk factors, laboratory values, the response of skin lesions to STS, and mortality. Results: 14 patients received STS for calciphylaxis over 5 years. Following STS administration, pain decreased in 71% of patients, and 70% had an improvement in their lesions. Those who did not improve or stabilize their skin lesions tended to have more advanced skin lesions, were on renal replacement therapy longer, were more obese and received less total dose of STS. However, despite STS, there was a 71% mortality rate, with 50% of subjects dying within 6 months. Conclusion: We conclude in this study of all subjects who received STS at our Institution that STS is an effective treatment for the pain and skin lesions of calciphylaxis if given in the early stages of disease and for a consistent period of time. However, there is little impact on overall mortality compared to historical published cohorts.

Original languageEnglish
Pages (from-to)485-490
Number of pages6
JournalClinical Nephrology
Volume75
Issue number6
DOIs
StatePublished - 2011

Fingerprint

Calciphylaxis
Skin
Therapeutics
Mortality
sodium thiosulfate
Pain
Publication Bias
Renal Replacement Therapy
Hospital Records
Chronic Kidney Failure
Medical Records

Keywords

  • Calcific uremic arteriolopathy
  • Cutaneous
  • End stage renal disease

ASJC Scopus subject areas

  • Nephrology

Cite this

Efficacy of sodium thiosulfate for the treatment for calciphylaxis. / Noureddine, L.; Landis, M.; Patel, N.; Moe, Sharon.

In: Clinical Nephrology, Vol. 75, No. 6, 2011, p. 485-490.

Research output: Contribution to journalArticle

Noureddine, L. ; Landis, M. ; Patel, N. ; Moe, Sharon. / Efficacy of sodium thiosulfate for the treatment for calciphylaxis. In: Clinical Nephrology. 2011 ; Vol. 75, No. 6. pp. 485-490.
@article{5f537b59582b4170b986d9c4d4147fd3,
title = "Efficacy of sodium thiosulfate for the treatment for calciphylaxis",
abstract = "Background/Aims: Calciphylaxis is a rare condition with dismal prognosis that affects patients with ESRD. Sodium thiosulfate (STS) may play a therapeutic role but its proposed efficacy is based on case reports and thus subject to publication bias. Methods: We identified all patients who received STS for any indication over a 5-year period through pharmacy records of 4 hospitals, retrospectively reviewing medical records for risk factors, laboratory values, the response of skin lesions to STS, and mortality. Results: 14 patients received STS for calciphylaxis over 5 years. Following STS administration, pain decreased in 71{\%} of patients, and 70{\%} had an improvement in their lesions. Those who did not improve or stabilize their skin lesions tended to have more advanced skin lesions, were on renal replacement therapy longer, were more obese and received less total dose of STS. However, despite STS, there was a 71{\%} mortality rate, with 50{\%} of subjects dying within 6 months. Conclusion: We conclude in this study of all subjects who received STS at our Institution that STS is an effective treatment for the pain and skin lesions of calciphylaxis if given in the early stages of disease and for a consistent period of time. However, there is little impact on overall mortality compared to historical published cohorts.",
keywords = "Calcific uremic arteriolopathy, Cutaneous, End stage renal disease",
author = "L. Noureddine and M. Landis and N. Patel and Sharon Moe",
year = "2011",
doi = "10.5414/CNP75485",
language = "English",
volume = "75",
pages = "485--490",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "6",

}

TY - JOUR

T1 - Efficacy of sodium thiosulfate for the treatment for calciphylaxis

AU - Noureddine, L.

AU - Landis, M.

AU - Patel, N.

AU - Moe, Sharon

PY - 2011

Y1 - 2011

N2 - Background/Aims: Calciphylaxis is a rare condition with dismal prognosis that affects patients with ESRD. Sodium thiosulfate (STS) may play a therapeutic role but its proposed efficacy is based on case reports and thus subject to publication bias. Methods: We identified all patients who received STS for any indication over a 5-year period through pharmacy records of 4 hospitals, retrospectively reviewing medical records for risk factors, laboratory values, the response of skin lesions to STS, and mortality. Results: 14 patients received STS for calciphylaxis over 5 years. Following STS administration, pain decreased in 71% of patients, and 70% had an improvement in their lesions. Those who did not improve or stabilize their skin lesions tended to have more advanced skin lesions, were on renal replacement therapy longer, were more obese and received less total dose of STS. However, despite STS, there was a 71% mortality rate, with 50% of subjects dying within 6 months. Conclusion: We conclude in this study of all subjects who received STS at our Institution that STS is an effective treatment for the pain and skin lesions of calciphylaxis if given in the early stages of disease and for a consistent period of time. However, there is little impact on overall mortality compared to historical published cohorts.

AB - Background/Aims: Calciphylaxis is a rare condition with dismal prognosis that affects patients with ESRD. Sodium thiosulfate (STS) may play a therapeutic role but its proposed efficacy is based on case reports and thus subject to publication bias. Methods: We identified all patients who received STS for any indication over a 5-year period through pharmacy records of 4 hospitals, retrospectively reviewing medical records for risk factors, laboratory values, the response of skin lesions to STS, and mortality. Results: 14 patients received STS for calciphylaxis over 5 years. Following STS administration, pain decreased in 71% of patients, and 70% had an improvement in their lesions. Those who did not improve or stabilize their skin lesions tended to have more advanced skin lesions, were on renal replacement therapy longer, were more obese and received less total dose of STS. However, despite STS, there was a 71% mortality rate, with 50% of subjects dying within 6 months. Conclusion: We conclude in this study of all subjects who received STS at our Institution that STS is an effective treatment for the pain and skin lesions of calciphylaxis if given in the early stages of disease and for a consistent period of time. However, there is little impact on overall mortality compared to historical published cohorts.

KW - Calcific uremic arteriolopathy

KW - Cutaneous

KW - End stage renal disease

UR - http://www.scopus.com/inward/record.url?scp=79960958949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960958949&partnerID=8YFLogxK

U2 - 10.5414/CNP75485

DO - 10.5414/CNP75485

M3 - Article

C2 - 21612750

AN - SCOPUS:79960958949

VL - 75

SP - 485

EP - 490

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 6

ER -